{
    "clinical_study": {
        "@rank": "144766", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive 100 mg JNJ-39823277 under fed condition."
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive 100 mg JNJ-39823277 under fasted condition."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of food on the bioavailability of\n      JNJ-39823277 and its active metabolite JNJ-40917006 when administered as a single oral dose."
        }, 
        "brief_title": "A Study of Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Participants", 
        "completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This is a randomized (the study medication is assigned by chance), open-label (all people\n      know the identity of the intervention), single-center, 2 treatment-sequence, and crossover\n      study (method used to switch participants from one treatment arm to another in a clinical\n      study). The study consist of 3 phases: a screening phase (within 21 days before medication\n      administration), a 2-period open-label treatment phase, during which each participant will\n      receive 1 of 2 open-label treatment sequences, and the end-of-study or withdrawal\n      assessments (within 7-11 days after the last dose of the study medication). Participants\n      will be randomly assigned to 1 of 2 treatment-sequences: Treatment Sequence AB (dosing in\n      fed [with food] condition followed by dosing in fasted [without food] condition) or\n      Treatment Sequence BA (dosing in fasted condition followed by dosing in fed condition).\n      Study medication administrations will be separated by a washout period (period when\n      receiving no treatment) of 7 to 14days. The study duration for each participant will be\n      approximately 6 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participant must be a healthy male or non-lactating healthy female\n\n          -  Agrees to protocol-defined use of effective contraception\n\n          -  If a woman, must have a negative serum \u00df-human chorionic gonadotropin (\u00df-hCG)\n             pregnancy test at screening and on Day -1 of each treatment period\n\n          -  Agree to abstain from all medication (except for allowed birth control), including\n             prescription and non-prescription (including vitamins and natural or herbal remedies)\n\n        Exclusion Criteria:\n\n          -  A history of clinically significant gastrointestinal, especially peptic ulcerations,\n             gastrointestinal bleeding, ulcerative colitis, Crohn's disease or Irritable Bowel\n             Syndrome, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary,\n             immunologic, psychiatric, especially those with a past history of depression,\n             suicidal ideation or suicidal attempts, or cardiovascular disease\n\n          -  Acute diarrhea or constipation in the 7 days before the predicted first study day. If\n             screen occurs >7 days before first study day, this criterion will be determined on\n             Day -1\n\n          -  Participant has donated blood within 90 days or plasma within 30 days of study dosing\n\n          -  Participant has used any over-the-counter or prescription medication, including\n             vitamins, within 14 days prior to the study with the exception of acetaminophen\n\n          -  Participant has consumed products containing grapefruit juice or grapefruit, Seville\n             oranges (eg, orange marmalade), quinine (eg, tonic water), or xanthine (eg,\n             chocolate, caffeine containing products) within 24 hours (72 hours in the case of\n             grapefruit juice and Seville oranges) prior to start of study drug administration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103985", 
            "org_study_id": "CR015718", 
            "secondary_id": "TPI1062DEP1004"
        }, 
        "intervention": {
            "arm_group_label": [
                "Treatment A", 
                "Treatment B"
            ], 
            "description": "Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.", 
            "intervention_name": "JNJ-39823277", 
            "intervention_type": "Drug", 
            "other_name": "TPI-1062"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy", 
            "JNJ-39823277", 
            "JNJ-40917006", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lincoln", 
                    "country": "United States", 
                    "state": "Nebraska"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-Label, Two-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Male and Female Subjects", 
        "overall_official": {
            "affiliation": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
            "last_name": "Johnson & Johnson Pharmaceutical Research and Development, L.L C. Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The Cmax is defined as maximum observed analyte concentration.", 
                "measure": "Maximum Observed Plasma Concentration (Cmax) of JNJ-39823277", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose; and 0.25, 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36 hours post-dose"
            }, 
            {
                "description": "The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-39823277", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose; and 0.25, 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36 hours post-dose"
            }, 
            {
                "description": "The AUClast is area under the plasma concentration-time curve from time zero to the last quantifiable concentration.", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of JNJ-39823277", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose; and 0.25, 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36 hours post-dose"
            }, 
            {
                "description": "The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of Area under Curve (AUC) last and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.", 
                "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of JNJ-39823277", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose; and 0.25, 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36 hours post-dose"
            }, 
            {
                "description": "The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda[z]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).", 
                "measure": "Elimination Half-Life Period (T1/2) of JNJ-39823277", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose; and 0.25, 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36 hours post-dose"
            }, 
            {
                "description": "The Cmax is defined as maximum observed analyte concentration.", 
                "measure": "Maximum Observed Plasma Concentration (Cmax) of JNJ-40917006 (MC5 metabolite)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose; and 0.25, 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36 hours post-dose"
            }, 
            {
                "description": "The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-40917006 (MC5 metabolite)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose; and 0.25, 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36 hours post-dose"
            }, 
            {
                "description": "The AUClast is area under the plasma concentration-time curve from time zero to the last quantifiable concentration.", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of JNJ-40917006 (MC5 metabolite)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose; and 0.25, 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36 hours post-dose"
            }, 
            {
                "description": "The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of Area under Curve (AUC) last and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.", 
                "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of JNJ-40917006 (MC5 metabolite)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose; and 0.25, 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36 hours post-dose"
            }, 
            {
                "description": "The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda[z]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).", 
                "measure": "Elimination Half-Life Period (T1/2) of JNJ-40917006 (MC5 metabolite)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose; and 0.25, 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103985"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events as a measure of safety and tolerabilty", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 6 weeks"
        }, 
        "source": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}